NEW YORK--(BUSINESS WIRE)--Deutsche Bank today announced that it will add two senior bankers to its Healthcare Investment Banking practice. Andrew Bhak and Peter Zippelius will join as Managing Directors and Co-Heads of Healthcare Services within Investment Banking Coverage (IBC). Both will be based in New York and will report to Michael Cohen, Global Head of Healthcare IBC.
Bhak joins Deutsche Bank after over seven years at Morgan Stanley where he played a pivotal role in helping build its Healthcare Services Investment Banking business. Prior to this, he spent three years at Deutsche Bank as a coverage banker and over 10 years as an Equity Research Analyst at Morgan Stanley, Goldman Sachs, and T. Rowe Price.
Zippelius also joins the firm from Morgan Stanley he was most recently a Managing Director in the Healthcare Investment Banking Group. Previously, Zippelius was in Citi’s Leveraged & Acquisition Finance Structuring and Origination group and began his career in Salomon Smith Barney’s M&A group.
“The healthcare industry remains dynamic and is a sector we have identified for investment in the Americas,” said Paul Stefanick, Head of Global Investment Banking Coverage & Advisory and Co-Head of Corporate Finance Americas. “Our Americas Healthcare franchise is the strongest it has ever been and the addition of Andrew and Pete will ensure we continue to broaden our capabilities for our clients.”
“We are pleased Andrew and Pete have decided to join our talented Healthcare team in the region,” said Cohen. “Their combined experience and track record across Healthcare Services Investment Banking adds further expertise to our client coverage.”
Deutsche Bank achieved a top three market share position in US Healthcare M&A for the first quarter of the year, according to Dealogic. The Bank also holds a top three ranking in the Medical Supplies & Devices sector and a top five position in the Specialty Pharma sector in the first quarter of the year.
The Bank recently closed transactions for Warner Chilcott’s sale to Actavis for USD 8.5bn; Life Technologies’ acquisition by Thermo Fisher for a total enterprise value of USD 15.8bn; Endo Health’s USD 1.6bn acquisition of Paladin Labs; and Mallinckrodt’s USD 1.3bn acquisition of Cadence Pharmaceuticals.